comprehensive -WSS

comprehensive

author：focus 2025-10-03 01:04:14 - browse：31

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： A Theranos scientist

hotspot

WSS

Why Eli Lilly’s earnings didn’t quite live up to the hype

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Flagship, Pfizer team up in deal worth up to $7 billion

ACIP vaccine advisory panel sees its vacancies filled

Why Eli Lilly’s earnings didn’t quite live up to the hype

Doctors on social media are being harassed and cyberbullied

focus

comprehensive

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Latigo launches with $135 million for Vertex

Duchenne breakthrough therapy leaves behind pioneering families

AMAs digital advisors table RPM coding reform proposal, again

How to save PrEP access — and even expand it

Lack of darker skin in textbooks, journals harms patients of color

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Amylyx, Aurinia, and IQVIA

The high cost of giving birth even with insurance

House passes resolution saying Israel isn't a 'racist or apartheid state'

entertainment

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Having children helps parents live longer, especially after age 80

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Johnson & Johnson sues to stop Medicare negotiation

BridgeBio heart drug succeeds in pivotal study

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

focus

entertainment

hotspot

focus